@article{fc5d2718458141bfa7bf0f410d1c03b2,
title = "Editorial: Strategies and barriers for hepatitis B cure: Implications for HIV",
author = "Revill, {Peter A.} and Lewin, {Sharon R.}",
note = "Funding Information: HBV cure is now recognized by the WHO as a key pillar in the strategies required to eliminate viral hepatitis as a public health problem by 2030 [22]. Funding bodies have recognized this unmet need, with the National Institute of Health (NIH) having recently announced a grant scheme dedicated specifically to HBV curative research [23]. More recently, the {\textquoteleft}Melbourne Declaration for Hepatitis B Cure{\textquoteright} [24] was endorsed by the 2019 International HBV Molecular Biology Meeting, calling for increased funding for HBV curative research and pledged to fast track efforts for HBV cure, particularly in the Asia-Pacific region where over 120 million people are living with HBV [25]. HBV cure efforts are being coordinated globally through organizations, such as the ICE-HBV [3–5,26], the Forum for Collaborative Research [10,11] and the Hepatitis B Foundation [27]. There is also strong interest and engagement from the pharmaceutical and biomedical sector, with many new drugs targeting different stages of the HBV replication cycle and immunomodulatory approaches in preclinical or early phase clinical trials [5,28].",
year = "2020",
month = may,
day = "1",
doi = "10.1097/COH.0000000000000620",
language = "English",
volume = "15",
pages = "151--156",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "3",
}